Preclinical evaluation of 131I-Bevacizumab — A prospective agent for radioimmunotherapy in VEGF expressing cancers

Kameswaran, M.Sarma, H. D.Dash, A.2017-09-052017-09-052017Applied Radiation and Isotopes, 2017. Vol. 123: pp. 109-113http://hdl.handle.net/123456789/148433879 bytestext/htmlenPreclinical evaluation131I-BevacizumabradioimmunotherapyVEGF expressing cancerPreclinical evaluation of 131I-Bevacizumab — A prospective agent for radioimmunotherapy in VEGF expressing cancersArticle